What 10,000+ Ultrasound Malfunction Reports in FDA MAUDE Really Tell Buyers, HTM, and Independent Service Teams

TL;DR

Hospital biomedical engineering (HTM) teams, independent service organizations (ISOs), and ultrasound procurement managers frequently turn to the U.S. FDA MAUDE database to assess equipment failure risk, evaluate replacement probes, or vet third-party service providers. However, treating raw report counts as an objective brand reliability scorecard creates false alarms and distorted risk assessments.

10-Year Dataset Scope:Across 10,442 diagnostic ultrasound medical device reports filed in FDA MAUDE between 2016 and 2026, the overwhelming majority document non-injurious hardware malfunctions rather than direct patient harm ¹ ⁶.
94.3% No-Harm Malfunctions:Over 94.3% of all diagnostic ultrasound reports (9,852 events) are classified as no-harm Malfunctions, with patient Injury accounting for 5.1% (529 events) and Death representing 0.47% (49 events). Within the diagnostic imaging console subset, malfunctions represent 95.2% of all entries ².
The Device-Class Conflation Trap:The generic 'ultrasound' query in MAUDE combines three fundamentally distinct device types: point-of-care vascular access systems (43.1% of reports, 4,501 events), diagnostic imaging consoles (36.5%, 3,809 events), and intravascular/endoscopic ultrasound catheters (12.2%, 1,279 events). Evaluating a general imaging console against this unsegregated total misinterprets the risk profile ⁴.
System vs. Transducer Failures:Among diagnostic reports detailing device architecture (2020–2025), imaging system console hardware represents 64.2% of reports (4,480 events) while transducers and probes represent 28.9% (2,017 events), demonstrating why thorough probe acoustic testing and board-level bench validation are vital acceptance controls.
Reporting Spikes vs. True Incidence:Annual submissions spiked from a 2016–2023 baseline of 600–900 reports per year to 1,912 in 2024 and 1,706 in 2025. This surge was primarily driven by mandatory post-market surveillance campaigns and manufacturer field corrections (such as the Philips transducer correction) rather than sudden changes in equipment reliability.
Actionable HTM Strategy:MAUDE should be utilized as a qualitative defect-discovery tool—highlighting which circuit boards, acoustic arrays, and software versions require stringent bench testing during incoming acceptance—rather than as a commercial brand-ranking metric ³ ⁵.

Regulatory Notice: All figures originate from an FDA MAUDE post-market reporting snapshot (2016–2026 data). Per official FDA and openFDA guidance, MAUDE is a passive surveillance repository; report volumes reflect mandatory manufacturer compliance activity and installed base scale rather than verified failure incidence or comparative device safety.

What Do 10,000+ Ultrasound MAUDE Reports Actually Mean for Buyers and HTM Teams?

When clinical engineering directors, hospital procurement committees, and independent service providers evaluate a used ultrasound system, a replacement transducer, or a third-party repair partnership, querying the U.S. Food and Drug Administration's Manufacturer and User Facility Device Experience (MAUDE) database is often their first due-diligence step ³. Seeing hundreds of adverse event entries for a premier ultrasound model often triggers immediate concern. But what do these reports actually represent?

The direct answer is that FDA MAUDE for ultrasound is fundamentally a hardware malfunction registry, not a clinical harm scorecard. Across 10,442 diagnostic ultrasound reports logged between 2016 and mid-2026, 94.3% (9,852 reports) are classified as no-harm Malfunctions where an equipment fault occurred without causing any patient injury ¹ ². Patient injuries represent 5.1% (529 reports, predominantly minor procedural delays or superficial skin abrasions), and patient deaths represent 0.47% (49 reports over a decade, in records where the underlying medical emergency—rather than the imaging modality—was typically the primary clinical factor). The true denominator of clinical ultrasound examinations is not recorded in MAUDE, so these counts describe the volume of reports filed, not a harm rate.

Crucially, the public search term 'ultrasound' in MAUDE creates a serious analytical distortion. It aggregates three completely dissimilar medical device categories into a single data bucket: high-volume disposable point-of-care vascular access guidance tools (43.1% of all entries), stationary diagnostic imaging consoles (36.5%), and invasive intravascular/endoscopic catheters (12.2%) ⁴. Furthermore, the FDA explicitly mandates that Medical Device Reporting (MDR) data cannot be used to calculate device failure incidence or establish clinical causality ¹. Over 95.3% of all diagnostic ultrasound reports are submitted directly by device manufacturers fulfilling statutory compliance obligations under 21 CFR Part 803, meaning report volume tracks manufacturer post-market surveillance discipline and market share rather than hardware defect rates.

For healthcare technology management (HTM) professionals, biomedical engineers, and refurbished equipment buyers, MAUDE is highly valuable when used correctly: not as a brand reliability ranking, but as an empirical defect guide that reveals which failure modes (power supply dropouts, beamformer channel degradation, transducer acoustic lens delamination, and software freeze states) must be rigorously validated during incoming ultrasound probe acceptance testing and board-level verification.

What Is the FDA MAUDE Database—and What Are Its Statutory Limitations?

Under the federal Medical Device Reporting (MDR) regulation (21 CFR Part 803), device manufacturers, importers, and user facilities (hospitals and ambulatory surgical centers) are legally required to report certain device-related adverse events and product malfunctions to the FDA ¹. Voluntary submissions are also accepted from healthcare professionals, clinical engineers, and patients via MedWatch (Form FDA 3500) ².

Mandatory reporting is triggered under specific statutory conditions:

Manufacturer & Importer Reporting: Device manufacturers must submit an MDR within 30 calendar days of becoming aware of information reasonably suggesting that one of their marketed devices may have caused or contributed to a death or serious injury, or has malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur ¹.
User Facility Reporting: Hospitals and healthcare facilities must report suspected medical device-related deaths to both the FDA and the manufacturer within 10 work days, and serious injuries to the manufacturer (or to the FDA if the manufacturer is unknown) ¹.
5-Day Reports: If an adverse event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health, manufacturers must submit a report within 5 work days.

While MAUDE provides an essential post-market safety surveillance signal for regulators, the FDA publishes a strict, unequivocal disclaimer regarding how this data may and may not be interpreted ¹ ⁵:

MDR data is not intended to be used either to evaluate rates of adverse events, evaluate a change in event rates over time, or to compare adverse event occurrence rates across devices. The incidence, prevalence, or cause of an event cannot be determined from this reporting system alone due to under-reporting of events, inaccuracies in reports, lack of verification that the device caused the reported event, and lack of information about frequency of device use.— U.S. FDA — Limitations of Medical Device Reporting (MDR) Data, About the MAUDE Database

Why does the FDA prohibit comparative incidence calculations from MAUDE? The agency highlights four fundamental methodological constraints ¹ ²:

Passive Surveillance & Underreporting: Unlike clinical trials or active registries, MAUDE relies on passive reporting. The true denominator (the exact number of ultrasound scans performed globally or active machines in service) is unknown.
Lack of Independent Verification: Reports submitted to MAUDE are not systematically independently verified by FDA biomedical engineers prior to entry into the database. Anecdotal or unverified assertions are recorded as submitted.
Duplicate & Overlapping Entries: A single physical equipment malfunction may generate multiple distinct MDR records if reported independently by the hospital user facility, the servicing distributor, and the original equipment manufacturer (OEM).
Reporting Discipline Disparities: A manufacturer with an aggressive, automated post-market compliance system will submit thousands of minor malfunction notices for harmless software restarts, whereas a manufacturer with less granular reporting workflows will show artificially lower counts in the database.

Malfunction vs. Harm: How Many Ultrasound Reports Involve Patient Injury or Death?

To establish the true clinical reality behind ultrasound adverse event data, we performed an empirical analysis across the openFDA medical device reporting database spanning 2016 through mid-2026 ² ⁶. We filtered the master dataset to include all entries classified under the Radiology specialty ('RA') with generic names containing ultrasound imaging terms, as well as all FDA diagnostic ultrasound product codes:

Product Code IYO (21 CFR 892.1560, Radiology): “System, Imaging, Pulsed Echo, Ultrasonic” — the diagnostic imaging consoles and carts (backplanes, processing engines, display sub-assemblies).
Product Code IYN (21 CFR 892.1550, Radiology): “System, Imaging, Pulsed Doppler, Ultrasonic” — pulsed-Doppler and color-flow imaging systems.
Product Code ITX (21 CFR 892.1570, Radiology): “Transducer, Ultrasonic, Diagnostic” — piezoelectric and CMUT imaging probes, cables, acoustic lenses, connectors.
Product Code JOP (21 CFR 870.2880, Cardiovascular): “Transducer, Ultrasonic” — cardiovascular ultrasound transducers, including intravascular (IVUS) and intracardiac echocardiography (ICE) catheters.
Product Codes HEM and HGL (21 CFR 884.2225 / 884.2960, Obstetric-Gynecologic): “Imager, Ultrasonic, Obstetric-Gynecologic” and “Transducer, Ultrasonic, Obstetric” — OB/GYN ultrasound imagers and probes.

Note that these six product codes already span three distinct FDA medical-specialty panels — Radiology, Cardiovascular, and Obstetric-Gynecologic — which foreshadows the device-class conflation problem analyzed below. Across this verified 10-year cohort of 10,442 diagnostic ultrasound reports, the breakdown by event type demonstrates that patient safety hazards in diagnostic ultrasound are exceptionally rare:

Event Classification	Total Reports (2016–2026)	Percentage Share	Diagnostic Console Subset	Clinical Context & Typical Failure Nature
Malfunction	9,852	94.35%	3,628 (95.25%)	Non-injurious hardware/software failure: boot loop, power supply shutdown, frozen screen, acoustic artifact, probe element dropout.
Injury	529	5.07%	146 (3.83%)	Predominantly minor or procedural: exam cancellation/delay requiring re-scan, superficial probe lens warming, mild skin abrasion from casing.
Death	49	0.47%	33 (0.87%)	Critical care/emergency scenarios where ultrasound was present during cardiac arrest or trauma; reports reflect underlying mortality rather than device lethality.
Other / Unspecified	12	0.11%	2 (0.05%)	Administrative inquiries, unclassified submissions, or ambiguous field descriptions.
Total Diagnostic Cohort	10,442	100.00%	3,809 (100.00%)	Complete 10-year diagnostic ultrasound post-market dataset across all verified product codes.

When we isolate the stationary and cart-based diagnostic imaging consoles (manufactured by major brands including GE Healthcare, Philips, Siemens Healthineers, Canon/Toshiba, Samsung Medison, Mindray, and Fujifilm/Hitachi), the malfunction proportion climbs even higher to 95.25% (3,628 out of 3,809 console reports). The patient problem narrative fields in these records predominantly document 'No Clinical Signs or Symptoms' or 'No Consequences to Patient'—confirming that the clinical workflow was stopped safely when the equipment failed.

Why the 'Ultrasound' MAUDE Pool Mixes Consoles, Vascular Access, and Intravascular Catheters

One of the most dangerous analytical traps for hospital HTM departments is conducting a generic MAUDE keyword search for 'ultrasound' and assuming the resulting report volume reflects standard radiology and cardiology ultrasound cart reliability. In reality, the FDA classification architecture encompasses vastly different clinical instruments under acoustic terminology ² ⁴.

Classifying each of the 10,442 reports by manufacturer, brand, and generic-name keywords (a heuristic over free-text fields, so the category shares are approximate rather than exact), the diagnostic-ultrasound pool decomposes into three distinct hardware segments:

Device Category	Report Count (2016–2026)	Share of Pool	Primary Device Types & Brands	Operational Risk & Failure Characteristics
Point-of-Care Vascular Access Systems	4,501	43.10%	Site-Rite (Bard/BD), Volcano, vascular needle guidance systems, portable bedside access units	High-volume procedural tools in ICU/ED; high mechanical wear, dropped handpieces, sterile sheath tears, guidewire interference.
Diagnostic Imaging Consoles & Carts	3,809	36.48%	GE (LOGIQ/Voluson/Vivid), Philips (EPIQ/Affiniti/iU22), Siemens (Sequoia/S2000), Mindray, Canon Aplio, Samsung	Multi-board console backplanes, power distribution units, front-end beamformers, processing engines, cart display monitors.
Intravascular & Endoscopic Ultrasound (IVUS / EUS)	1,279	12.25%	Olympus EUS scopes, Boston Scientific IVUS catheters, specialized intracardiac echocardiography (ICE) catheters	Invasive lumens, articulating scope distal tips, elevator wire wear, working-channel fluid ingress, biopsy needle channel scoring.
Other / Unclassified Ultrasound	853	8.17%	Niche Doppler units, research acoustic modules, unmapped regional devices	Miscellaneous laboratory, peripheral Doppler, or incomplete legacy metadata entries.

Notice that Point-of-Care vascular access devices represent the largest single share of reports (43.10%, 4,501 reports), exceeding the entire diagnostic imaging console fleet combined (36.48%). For instance, the public MAUDE search portal regularly surfaces Bard Site-Rite needle-guidance entries as top 'ultrasound' results ³. These bedside devices operate in high-turnover emergency and vascular nursing environments where physical dropping, cable pinching, and sterile fluid exposure occur constantly.

Similarly, peer-reviewed literature examining endoscopic ultrasound (EUS) in MAUDE demonstrates that invasive EUS scopes experience unique channel puncture and bending section failures that have zero relevance to a standard convex or cardiac phased-array probe ⁴. If an HTM director pools all ultrasound data together, the high report counts of disposable vascular guidance wands and invasive scopes distort the reliability benchmarks of diagnostic imaging carts.

System Consoles vs. Transducers: Where Do Hardware Failures Cluster?

For biomedical engineers planning maintenance schedules and spare-parts inventory, understanding where physical hardware failures originate within the diagnostic imaging chain is vital. We analyzed diagnostic ultrasound submissions between 2020 and 2025 where the generic device name explicitly designated either system-level hardware or transducer assemblies ²:

Imaging System Console Hardware (64.2% / 4,480 reports): Encompasses power supply failures, system backplane communication timeouts, beamformer channel loss, backend CPU/GPU processing board lockups, software operating system exceptions, and control panel touch screen freezes. System faults typically manifest as no-power conditions, boot loops, or software error dialogue boxes.
Ultrasound Transducers & Probes (28.9% / 2,017 reports): Encompasses piezoelectric crystal element dropouts, acoustic lens delamination, housing cracks, cable strain relief splitting, connector pin bending, and lens surface temperature rises. Probe faults manifest as vertical black shadowing artifacts, Doppler sensitivity loss, or interlock communication errors.
Other & Peripheral Assemblies (6.9% / 477 reports): Encompasses foot switches, peripheral thermal video printers, external DICOM gateways, and battery management sub-modules.

This empirical split reinforces a critical clinical reality: while the console houses the majority of complex electronic sub-assemblies (accounting for nearly two-thirds of reports), transducers account for nearly 30% of all reported hardware incidents despite representing only one peripheral attachment. Probes are handheld, constantly disinfected, repeatedly dropped, and subjected to mechanical flex stress during every patient scan. For the roughly two-thirds of reports that trace to console hardware, our companion ultrasound board-level failure-patterns field guide maps those console malfunctions to specific boards and root causes; this article stays focused on how to read the MAUDE record itself.

This finding directly supports the implementation of strict ultrasound probe acceptance testing protocols. An incoming replacement probe—whether sourced from an OEM or an independent supplier—must undergo electrical safety leakage testing, acoustic array element sensitivity testing using an acoustic phantom, and microscopic lens inspection before clinical release.

What Drove the 2024–2025 Reporting Surge? Surveillance Artifacts vs. True Defect Rates

A historical longitudinal examination of diagnostic ultrasound MAUDE submissions by year reveals a stable baseline followed by a dramatic reporting surge ² ⁶:

2016–2020 (Stable Baseline): Annual submissions averaged 692 reports per year (2016: 670; 2017: 801; 2018: 589; 2019: 715; 2020: 688).
2021–2023 (Post-Pandemic Growth): Submissions rose moderately to 988 in 2021, 786 in 2022, and 894 in 2023, tracking post-pandemic clinical procedure volume recovery.
2024–2025 (The Surveillance Surge): Submissions jumped sharply to 1,912 reports in 2024 and 1,706 reports in 2025—more than doubling the historical baseline.
2026 (Partial Year Snapshot): 693 reports recorded through the mid-2026 data capture point.

Did ultrasound equipment suddenly become twice as failure-prone in 2024 and 2025? Absolute not. An in-depth audit of the manufacturer-level reporting distribution reveals that this spike was heavily concentrated in specific post-market surveillance audits and field safety corrective actions.

In particular, extensive post-market reviews of ultrasound transducer useful life, refurbished probe labeling, and imaging software revisions—exemplified by the Philips S5-2 transducer field correction and the subsequent September 2025 FDA Warning Letter to Royal Philips (CMS #709948)—prompted massive retrospective MDR filing campaigns across global installed bases ¹. When an OEM initiates a field correction under 21 CFR Part 806, every customer complaint received during the retrospective investigation window is batched and submitted into MAUDE as an individual MDR.

This phenomenon highlights why raw year-over-year report counts reflect regulatory compliance intensity and reporting triggers rather than a sudden degradation in physical equipment reliability. As documented in our sibling analysis of 527 FDA ultrasound recalls and failure modes, regulatory enforcement spikes must be understood in their proper administrative context.

MAUDE Malfunction Reports vs. FDA Recalls: Which Database Should You Check and When?

Biomedical engineers and healthcare procurement officers often confuse the FDA MAUDE database with the FDA Recall Enterprise System (RES). While both databases serve medical device post-market oversight, they capture entirely different stages of the safety lifecycle and require different operational responses ¹ ².

Comparison Dimension	FDA MAUDE Database (21 CFR Part 803)	FDA Recall Database / RES (21 CFR Part 806 / Part 7)
Data Nature & Origin	Bottom-up, event-driven passive surveillance reports filed after an individual field malfunction, injury, or death.	Top-down, formal regulatory field corrections, software patches, or product removals initiated by the manufacturer or mandated by FDA.
Verification Level	Unverified field submissions; includes subjective user accounts, raw complaints, and mandatory compliance filings.	Confirmed, legally verified regulatory actions with assigned Recall Class (Class I, II, or III) and root-cause determination.
Primary Use for HTM / Buyers	Qualitative defect discovery: identifies what failure modes, board subsystems, and probe components to test during intake.	Compliance & safety verification: confirms whether a specific serial/lot number requires mandatory firmware updates or hardware replacement.
Analytical Guardrail	Cannot calculate failure incidence, defect rates, or compare brand safety.	Recall counts reflect corporate surveillance rigor and model portfolio width, not overall fleet danger.
When to Query	When defining incoming acceptance-test checklists for a new model family or vetting third-party board repair capabilities.	Before purchasing a used system or probe, and during routine quarterly fleet safety audits.

In summary: check the FDA Recall Database (RES) to ensure an incoming asset does not have outstanding open safety notices or mandatory software patches. Check FDA MAUDE to understand which board-level subsystems, power rails, and acoustic transducer components have historically exhibited field vulnerabilities, allowing you to tailor your bench testing accordingly.

How HTM and Procurement Teams Should Actually Use MAUDE for Equipment Qualification

Rather than treating MAUDE as a passive repository of alarming headlines, high-performing biomedical engineering departments transform MDR data into an actionable engineering input. Follow this 4-step qualification protocol when evaluating a new ultrasound model family, a used equipment lot, or an independent service partner ³ ⁵:

Step 1: Isolate by Specific FDA Product Code & Console Model: Never perform an unsegregated keyword search. Query MAUDE using the exact 3-letter product code (IYO for consoles, ITX for transducers) combined with the exact manufacturer model name (e.g., 'LOGIQ E9', 'EPIQ 7', 'Vivid E95'). Disregard entries belonging to point-of-care vascular access units or invasive catheter systems.
Step 2: Map Malfunction Narratives to Hardware Subsystems: Filter for 'Malfunction' events and review the text summaries. Identify whether reported failures cluster in power distribution units (PDU boot loops), front-end beamformer boards (channel loss artifacts), backend processing engines (OS freeze states), or probe connector assemblies.
Step 3: Build Targeted Bench Acceptance Checklists: Use the identified failure modes to create rigorous incoming inspection protocols. If MAUDE data for a specific model reveals recurrent power rail instability, mandate a minimum 48-hour burn-in stress test under full acoustic load prior to clinical deployment.
Step 4: Audit Third-Party Service & Repair Capabilities: When vetting an independent service organization (ISO) for board-level repairs or replacement parts, ask direct technical questions based on MAUDE failure modes: 'How does your testing facility verify front-end channel sensitivity?' and 'What real-machine burn-in evidence is provided with power supply repairs?'

Where Does Independent Ultrasound Servicing Stand in Post-Market Safety Data?

In debates surrounding right to repair and independent ultrasound servicing, OEM commercial advocacy occasionally cites MAUDE malfunction volume to suggest that servicing medical equipment outside factory networks introduces patient risk. However, empirical analyses by both the FDA and independent academic researchers contradict this assertion ¹ ⁵.

In the FDA's comprehensive Report on the Quality, Safety, and Effectiveness of Servicing of Medical Devices (issued pursuant to Section 710 of the FDA Reauthorization Act of 2017), the agency conducted an exhaustive review of MAUDE MDR data, ECRI databases, and hospital safety records. The FDA concluded that the available objective evidence does not demonstrate that third-party servicing presents a disproportionate safety hazard, and that both OEM and independent service organizations provide high-quality, safe maintenance when adhering to proper quality systems ¹.

Furthermore, under FDA regulatory guidance, legitimate servicing—defined as restoring a device to its original performance and safety specifications without altering its intended use—is clearly distinguished from remanufacturing ¹. For a comprehensive breakdown of these legal and technical boundaries, review our detailed guide on ultrasound servicing vs remanufacturing under FDA guidance.

What matters to patient safety is not the corporate label of the service provider, but the engineering rigor, component-level traceability, and real-machine validation applied to every repaired circuit board and transducer. When qualifying an independent partner, healthcare facilities should rely on verified quality management benchmarks, such as those detailed in our guide to qualifying a component-level ultrasound board repair provider.

Where Rongtao Medical fits—and where it does not

Navigating ultrasound parts sourcing, probe repairs, and fleet maintenance requires absolute transparency regarding technical capabilities and service boundaries.

Where Rongtao Medical Fits:

Component-Level Ultrasound Board Repair: We provide expert, component-level circuit board repair for GE, Philips, Siemens, Mindray, Toshiba/Canon, Hitachi/Fujifilm, and Samsung Medison systems—repairing power supplies, front-end beamformer boards, processing backplanes, and control panels.
Tested Replacement Probes & Modules: We supply fully tested, pre-owned original transducers and replacement circuit modules, verified on actual OEM ultrasound consoles prior to shipment.
Real-Machine Test Evidence: Every repaired board or probe is shipped with complete real-machine test documentation, acoustic phantom verification, and a standard 90-day warranty with typical 5–8 business-day turnaround.
Multi-Brand Inventory & EOSL Support: We maintain extensive inventory for current and end-of-service (EOSL) ultrasound systems to keep hospital fleets operational.

Where Rongtao Medical Does Not Fit:

No OEM Authorization or Affiliation: Rongtao Medical is an independent service provider. We do not represent ourselves as an authorized OEM service center or affiliated distributor.
No Software Binary Modifications: We do not modify OEM operating system binaries, bypass software licensing, or alter clinical diagnostic calculation algorithms.
No Clinical Reprocessing Services: We do not provide hospital-site high-level disinfection (HLD) or clinical reprocessing services.

Quote-ready buyer checklist: What to prepare before sourcing ultrasound probes or boards

When an ultrasound system experiences a hardware fault or a probe fails incoming acceptance testing, rapid clinical turnaround depends on complete technical data. Preparing full diagnostic documentation upfront eliminates guesswork and accelerates quote precision.

Before requesting a technical quote or dispatching a board/probe for repair, prepare the following 5-point evidence package:

1. System Identification: Exact OEM brand, system model name, and installed software/hardware revision (e.g., GE Voluson E10 BT18, Philips EPIQ 7 Software v4.0.1, Siemens SC2000 Prime).
2. Part or Transducer Identification: Complete manufacturer part number, assembly part number, and serial number (e.g., GE C1-5-D Probe Part #5393900; Philips Power Supply Part #453561412341).
3. Visual Label Documentation: Clear, high-resolution photographs showing both sides of the circuit board, component labels, PCB revision markings, and barcode stickers.
4. Detailed Symptom & Error Code Description: Exact clinical failure behavior (e.g., 'System powers on, cooling fans run at high speed, but display stops at boot screen with Beamformer Comm Error 0x004', 'Vertical acoustic dropout across lateral 15% of linear array image').
5. Operational Handoff Details: Required turnaround timeframe, quantity, and destination delivery address.

Frequently Asked Questions

Q1: Can I use MAUDE report counts to say one ultrasound brand is safer than another?
No. The FDA explicitly prohibits using MAUDE MDR data to calculate adverse event rates or compare safety across manufacturers. MAUDE is a passive surveillance repository; report volumes reflect total installed equipment base size, corporate reporting discipline, and mandatory post-market surveillance campaigns rather than true product reliability.

Q2: Why do so many ultrasound MAUDE reports show 'No Clinical Signs' or 'No Consequences' as the patient problem?
Under 21 CFR Part 803, manufacturers must report any device malfunction that would be likely to cause or contribute to a death or serious injury if the malfunction were to recur—even if the actual event caused zero patient harm. Because diagnostic ultrasound has multiple safety interlocks (such as thermal cutoffs and watchdog timers), the vast majority of hardware failures result in safe system shutdown with no clinical impact on the patient.

Q3: What is the difference between a MAUDE malfunction report and an FDA recall for an ultrasound system or probe?
A MAUDE report is a bottom-up field submission detailing an individual alleged malfunction or adverse event. An FDA Recall (logged in RES) is a confirmed, top-down regulatory action where the manufacturer formally initiates a field correction, software patch, or physical removal to rectify a verified systemic defect across a product batch.

Q4: How current is the MAUDE data, and how often should I re-check a model or probe before purchase?
FDA updates the public MAUDE database monthly. Biomedical departments should check MAUDE and the FDA Recall database during the initial evaluation of any new model family, when sourcing pre-owned inventory lots, and during annual fleet safety reviews.

Q5: How can HTM teams use MAUDE data to improve incoming probe and board acceptance testing?
By reviewing the specific hardware failure modes reported for a model family in MAUDE, biomedical engineers can design targeted acceptance tests. For example, if MAUDE records show recurring acoustic lens delamination or front-end channel dropouts for a specific probe type, incoming inspection should mandate acoustic phantom scanning, element sensitivity profiling, and high-pot electrical leakage testing before releasing the probe to clinical service.